The National Institute of Allergy and Infectious Diseases (NIAID) has announced that it will halt its HVTN 505 HIV vaccine trial due to a perceived lack of efficacy. A scheduled review by an independent data and safety monitoring board found that the vaccine regimen neither prevented HIV infection nor reduced viral load in vaccine recipients who became infected with HIV.
The announcement will come as a blow to those hoping the HVTN 505 would be an effective intervention to stem the HIV pandemic. However, IAVI CEO Margie McGlynn said ““We know that these trials, even those that do not achieve their goals, play an important role in informing HIV vaccine development.”
The prime-boost regimen comprised a DNA-based vaccine candidate and an adenovirus serotype 5-based candidate. The study had been running since 2009, and enrolled over 2500 volunteers from across 19 US cities. There was in fact a non-statistically significant increase in acquisition of HIV among the vaccinated group compared to the placebo group – a total of 41 cases of HIV infection occurred in the volunteers who received the investigational vaccine regimen and 30 cases of HIV infection occurred among the placebo vaccine recipients. The cause of this increase is unknown and is being investigated.
What do you think? Are you surprised or disappointed by the news? You can join our discussion on LinkedIn or leave a comment below, I’d love to hear what you think.
HIV vaccine design and clinical trials were discussed at the World Vaccine Congress USA 2013 – Read more here >> If you want to know more about strategy and innovation in vaccines, you might be interested in attending the World Vaccine Congress Asia 2013, 17-20 June 2013, Singapore.
Want more from Vaccine Nation? Sign up to our newsletter for free here.